NEW YORK, March 1 - Aurora Biosciences said Thursday it completed its acquisition of Panvera, a Madison, Wisc.-based manufacturer of recombinant protein drug targets and protein drug screening assays.

Under the terms of the agreement, which has been approved by Panvera shareholders, Aurora will issue up to 1.9 million shares of its common stock in the transaction.

On November 17, the day the deal was originally announced, Aurora’s stock was trading just above $45 a share. Since then, the price has steadily fallen to about $18 a share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.